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tional Classiﬁcation of Diseases (ICD-9-CM) codes and
variables denoting disability days. Indirect costs due to
asthma-related absenteeism were calculated using the
human capital approach. Sample estimates were weighted
and projected to the population and 95% conﬁdence
limits for estimates were calculated using the Taylor
expansion method. RESULTS: Indirect costs of asthma
patients who missed workdays were $4,052,758,837
with mean indirect costs of $2,880 per patient (95% C.L.
= $1,253 to $4,507). Relative to the entire population,
mean indirect costs per person were $15. CONCLU-
SIONS: Productivity losses due to asthma were sizeable,
with total indirect costs greater than $4 billion and mean
indirect costs nearly $3000. With such work place con-
sequences, additional studies of indirect costs resulting
from asthma should be conducted in the U.S. and other
countries to comprehensively quantify the costs of asthma
and to further develop and implement responsive guide-
lines for diagnosis and treatment.
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Inhaled corticosteroids (ICS) provide different patients-
reported and economic outcomes. OBJECTIVE: We thus
compared the cost-utility of the most frequently pre-
scribed ICS in an Italian adult population with intrinsic
persistent asthma: beclomethasone (BDP), beclometha-
sone-extraﬁne (BDP-EF), ﬂuticasone and budesonide.
METHOD: We built a 7-state Markov tree: each state
corresponded to a utility level, as deﬁned by the Asthma
Symptom Utility Index. Transition probabilities were
derived from published randomized clinical trials, after
conversion of symptom-free days to utility. Frequency of
resource use within each health state was obtained
through a structured interview to nine pneumologists and
general practitioners. Unit costs for drugs, primary care,
hospital care and tests were derived from the 2002 Italian
Formulary and national charges. Patients lost productiv-
ity was valued according to the average national income.
Quality-adjusted days (QADs) were the unit of measure
for clinical utility. RESULTS: The analysis calculated that
BDP-EF was the most effective ICS, leading to an average
quality of life that was 3–6% higher than that of the other
ICS, that is 0.5 to 2.3 incremental QADs. From the soci-
etal perspective, the overall cost for 2 months asthma-
related health care ranged from €548 to €812 (higher for
severe asthma): BDP-EF was associated with the lowest
cost. BDP-EF was also associated with a lower cost per
QAD than ﬂuticasone: €13.4 versus €15.5 in moderate
asthma and €20.3 versus €20.9 in severe asthma. The
costs were lower from the perspective of the Health Care
System, although, BDP-EF was still the cheapest ICS, with
costs of €6.8 and €11.2 per QAD in moderate and severe
asthma patients, respectively. CONCLUSION: Through
sensitivity analysis we calculated that unitary cost of ﬂu-
ticasone should be decreased by 60–80% to make it as
cost-effective as BDP, however, it would still be domi-
nated (i.e. more expensive and less effective) by BDP-EF.
BDP-EF is actually the most cost-effective ICS in the
Italian setting.
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OBJECTIVES: Asthma creates a heavy economic burden
on Chinese patients and society. Therefore, it is impor-
tant to consider the economic impact of alternative treat-
ment options for asthma to ensure effective Health care
resource allocation. METHODS: A retrospective eco-
nomic analysis was conducted as part of a multicentre,
randomized, open-label, 6-week comparative trial of sal-
meterol/ﬂuticasone propionate combination product
(SFC) 50/100mg twice daily vs. budesonide 400mg twice
daily in 386 adults with asthma who were symptomatic
despite treatment with inhaled steroids at doses of 500mg
daily. Treatment effectiveness was measured in terms of
successfully-treated weeks, deﬁned as a ≥5% improve-
ment in morning peak expiratory ﬂow, episode-free days
(a day without symptom and the need for rescue med-
ication) and symptom-free days. Cost-effectiveness analy-
ses were performed using direct Health care costs with
sensitivity analysis analysis to test the robustness of the
ﬁndings. RESULTS: SFC produced signiﬁcantly higher (P
< 0.0001) proportions of successfully-treated weeks,
episode-free days, and symptom-free days. Direct asthma
management costs were similar between the two groups
[US$13.2 for SFC vs. US$11.7 for budesonide per week].
The cost per successful-treated week was lower for SFC
than for budesonide [$18.6 vs. $20.0 per week], as were
the costs per episode-free day [$4.21 vs. $6.12 per day]
and symptom-free day [$4.04 vs. $6.10 per day]. Incre-
mental cost-effectiveness ratios showed that the addi-
tional costs to achieve additional beneﬁts with SFC were
minimal. Costs per additional successful-treated week,
symptom-free day and episode-free day with SFC were
$12.3, $1.1 and $1.26 respectively relative to budesonide.
Sensitivity analysis showed that the results were stable
over a wide range of assumptions. CONCLUSIONS: The
results suggest that SFC 50/100mg bd. is a more cost-
effective treatment than four-fold higher dose of budes-
onide (400mg bd.) in the management of asthma who are
symptomatic on their existing dose of steroid.
